Bridgebio Pharma Inc

2026. g. 11. sept. 19:56 UTC

BBIO lower as JPMorgan cuts price target to $23.00.

2026. g. 10. sept. 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering sharply despite being below its 20-day moving average and near a one-month low.

2026. g. 9. sept. 22:46 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, despite no specific news. Broader market pressure persists from rising crude oil prices above $100.

2026. g. 2. sept. 19:36 UTC

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

2026. g. 1. sept. 23:16 UTC

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

2026. g. 28. aug. 20:08 UTC

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

2026. g. 20. aug. 19:46 UTC

Shares lower amid broader biotechnology sector decline.

2026. g. 19. aug. 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

2026. g. 18. aug. 20:06 UTC

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

2026. g. 14. aug. 20:06 UTC

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

2026. g. 13. aug. 23:01 UTC

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

2026. g. 12. aug. 19:51 UTC

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

2026. g. 11. aug. 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

2026. g. 10. aug. 23:21 UTC

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

2026. g. 7. aug. 20:03 UTC

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

2026. g. 6. aug. 19:16 UTC

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

2026. g. 5. aug. 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

2026. g. 4. aug. 19:36 UTC

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

2026. g. 3. aug. 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

2026. g. 31. jūl. 19:56 UTC

BBIO shares decline, continuing a three-day trend amid sector weakness.

2026. g. 30. jūl. 20:21 UTC

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

2026. g. 29. jūl. 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

2026. g. 28. jūl. 19:07 UTC

BBIO shares lower today amid declining biotech sector sentiment.

2026. g. 27. jūl. 18:26 UTC

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.